Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 18/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.77 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246557 | 0.97 | CHRNA7 (0.76) | CHRNA7KCNH2ADCY1TDP1 | |
| SCHEMBL13878545 | 0.87 | CHRNA7 (0.74) | CHRNA7KCNH2ADCY1 | |
| SCHEMBL4242097 | 0.87 | CHRNA7 (1.00) | CHRNA7KCNH2 | |
| SCHEMBL4238535 | 0.86 | CHRNA7 (0.59) | CHRNA7KCNH2TDP1 | |
| SCHEMBL13878544 | 0.86 | CHRNA7 (0.72) | CHRNA7KCNH2ADCY1 | |
| SCHEMBL13878542 | 0.86 | CHRNA7 (0.67) | CHRNA7KCNH2ADCY1TDP1 | |
| SCHEMBL4251616 | 0.86 | CHRNA7 (0.66) | CHRNA7KCNH2ADCY1 | |
| SCHEMBL4241965 | 0.85 | CHRNA7 (0.67) | CHRNA7KCNH2 | |
| Trifluoroacetic Acid SCHEMBL4243421 | 0.85 | CHRNA7 (0.67) | CHRNA7KCNH2ADCY1TDP1 | |
| SCHEMBL4247664 | 0.85 | CHRNA7 (0.57) | CHRNA7KCNH2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
| WO-2007138033-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105217-A1 | 2-PHENYL-5-AMINO-1,3,4-OXADIAZOLES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885KCNH2 815/4885ADCY1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.